AbiVax falls as safety worries cloud ‘landmark’ immune drug results
BioPharma Dive
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as best-in-disease and sent shares down more than 30%.
pharminent
June 2, 2026 (Last updated: June 3, 2026)
BioPharma Dive
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as best-in-disease and sent shares down more than 30%.
